Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Marcus

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
The Journal of Clinical Psychiatry|January 20, 2006
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studiesJan Volavka, Pal Czobor, Leslie Citrome, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|July 2, 2008
A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer diseaseJoel E Streim, Anton P Porsteinsson, Christopher D Breder, et al.
International Journal of Psychiatry in Clinical Practice|February 3, 2012
Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptomsMichael E Thase, Charles L Bowden, Michael Nashat, et al.
Bipolar Disorders|February 15, 2012
Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392)Berit X Carlson, Terence A Ketter, Wei Sun, et al.
Postgraduate Medicine|January 26, 2019
A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggressionAdelaide S Robb, Stefan Schwabe, Gianpiera Ceresoli-Borroni, et al.
Joint Commission Journal on Quality and Patient Safety|January 19, 2008
John M. Eisenberg Patient Safety and Quality Awards. Impact of CRM-based training on obstetric outcomes and clinicians' patient safety attitudesStephen D Pratt, Susan Mann, Mary Salisbury, et al.
The Primary Care Companion for CNS Disorders|July 7, 2011
Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studiesAdelaide S Robb, Candace Andersson, Elizabeth E Bellocchio, et al.
Schizophrenia Research|May 6, 2003
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trialsStephen R Marder, Robert D McQuade, Elyse Stock, et al.
The British Journal of Psychiatry : the Journal of Mental Science|September 2, 2005
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trialEduard Vieta, Michel Bourin, Raymond Sanchez, et al.
The American Journal of Psychiatry|February 4, 2026
Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension TrialInder Kaul, Amy Claxton, Colin Sauder, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The Journal of Clinical Psychiatry|January 20, 2006
Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studiesJan Volavka, Pal Czobor, Leslie Citrome, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|July 2, 2008
A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer diseaseJoel E Streim, Anton P Porsteinsson, Christopher D Breder, et al.
International Journal of Psychiatry in Clinical Practice|February 3, 2012
Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptomsMichael E Thase, Charles L Bowden, Michael Nashat, et al.
Bipolar Disorders|February 15, 2012
Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392)Berit X Carlson, Terence A Ketter, Wei Sun, et al.
Postgraduate Medicine|January 26, 2019
A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggressionAdelaide S Robb, Stefan Schwabe, Gianpiera Ceresoli-Borroni, et al.
Joint Commission Journal on Quality and Patient Safety|January 19, 2008
John M. Eisenberg Patient Safety and Quality Awards. Impact of CRM-based training on obstetric outcomes and clinicians' patient safety attitudesStephen D Pratt, Susan Mann, Mary Salisbury, et al.
The Primary Care Companion for CNS Disorders|July 7, 2011
Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studiesAdelaide S Robb, Candace Andersson, Elizabeth E Bellocchio, et al.
Schizophrenia Research|May 6, 2003
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trialsStephen R Marder, Robert D McQuade, Elyse Stock, et al.
The British Journal of Psychiatry : the Journal of Mental Science|September 2, 2005
Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trialEduard Vieta, Michel Bourin, Raymond Sanchez, et al.
The American Journal of Psychiatry|February 4, 2026
Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension TrialInder Kaul, Amy Claxton, Colin Sauder, et al.
Pageof 3